secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0001140361-25-027032
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma restructures, cuts headcount 30%, delays FA/PKD programs; cash runway to Q2 2027
--------------------------------------------------------------------------------

- Headcount reduction of ~30% and 12-month cash burn reduction of ~25% as part of corporate reorganization.
- Pipeline focus on AAV cardiovascular programs (Danon, PKP2-ACM, BAG3-DCM) and KRESLADI for severe LAD-I.
- Cash runway extended into Q2 2027; excludes any potential proceeds from Priority Review Voucher for KRESLADI.
- Fanconi Anemia (RP-L102) and Pyruvate Kinase Deficiency (RP-L301) programs delayed; FDA OK for RP-L102 no longer expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125027032/0001140361-25-027032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125027032/ef20052552_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-027032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer